Opposing effects of polyglutamine expansion on native protein complexes contribute to SCA1

Nature

Volumn 452, Issue 7188, 2008, Pages 713-718

  Lim, Janghoo ^a   Crespo Barreto, Juan ^a   Jafar Nejad, Paymaan ^a   Bowman, Aaron B ^a,e   Richman, Ronald ^a   Hill, David E ^b,c   Orr, Harry T ^d   Zoghbi, Huda Y ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAXIN 1; CAPICUA PROTEIN; POLYGLUTAMINE; PROTEIN; UNCLASSIFIED DRUG;

DISEASE; HERITABILITY; MODELING; NERVOUS SYSTEM DISORDER; PATHOLOGY; PROTEIN;

ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; MOLECULAR BIOLOGY; MOUSE; NEUROPATHOLOGY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; SPINOCEREBELLAR DEGENERATION;

EID: 42049086100     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature06731     Document Type: Article

References (43)

1. Orr, H. T. & Zoghbi, H. Y. Trinucleotide repeat disorders. Annu. Rev. Neurosci. 30, 575-621 (2007).
2. Harjes, P. & Wanker, E. E. The hunt for huntingtin function: interaction partners tell many different stories. Trends Biochem. Sci. 28, 425-433 (2003).
3. Li, S. H. & Li, X. J. Huntingtin-protein interactions and the pathogenesis of Huntington's disease. Trends Genet. 20, 146-154 (2004).
4. Matilla, A. et al. Mice lacking ataxin-1 display learning deficits and decreased hippocampal paired-pulse facilitation. J. Neurosci. 18, 5508-5516 (1998).
5. Yeh, S. et al. Generation and characterization of androgen receptor knockout (ARKO) mice: an in vivo model for the study of androgen functions in selective tissues. Proc. Natl Acad. Sci. USA 99, 13498-13503 (2002).
6. Zeitlin, S., Liu, J. P., Chapman, D. L., Papaioannou, V. E. & Efstratiadis, A. Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue. Nature Genet. 11, 155-163 (1995).
7. Kiehl, T. R. et al. Generation and characterization of Sca2 (ataxin-2) knockout mice. Biochem. Biophys. Res. Commun. 339, 17-24 (2006).
8. Klement, I. A. et al. Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice. Cell 95, 41-53 (1998).
9. Tsuda, H. et al. The AXH domain of ataxin-1 mediates neurodegeneration through its interaction with Gfi-1/senseless proteins. Cell 122, 633-644 (2005).
10. Emamian, E. S. et al. Serine 776 of ataxin-1 is critical for polyglutamine-induced disease in SCA1 transgenic mice. Neuron 38, 375-387 (2003).
11. McManamny, P. et al. A mouse model of spinal and bulbar muscular atrophy. Hum. Mol. Genet. 11, 2103-2111 (2002).
12. Katsuno, M. et al. Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Neuron 35, 843-854 (2002).
13. Chevalier-Larsen, E. S. et al. Castration restores function and neurofilament alterations of aged symptomatic males in a transgenic mouse model of spinal and bulbar muscular atrophy. J. Neurosci. 24, 4778-4786 (2004).
14. Sopher, B. L. et al. Androgen receptor YAC transgenic mice recapitulate SBMA motor neuronopathy and implicate VEGF164 in the motor neuron degeneration. Neuron 41, 687-699 (2004).
15. Graham, R. K. et al. Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due tomutant huntingtin. Cell 125, 1179-1191 (2006).
16. Warby, S. C. et al. Huntingtin phosphorylation on serine 421 is significantly reduced in the striatum and by polyglutamine expansion in vivo. Hum. Mol. Genet. 14, 1569-1577 (2005).
17. Luo, S., Vacher, C., Davies, J. E. & Rubinsztein, D. C. Cdk5 phosphorylation of huntingtin reduces its cleavage by caspases: implications for mutant huntingtin toxicity. J. Cell Biol. 169, 647-656 (2005).
18. Steffan, J. S. et al. SUMO modification of Huntingtin and Huntington's disease pathology. Science 304, 100-104 (2004).
19. Fernandez-Funez, P. et al. Identification of genes that modify ataxin-1-induced neurodegeneration. Nature 408, 101-106 (2000).
20. Lim, J. et al. A protein-protein interaction network for human inherited ataxias and disorders of Purkinje cell degeneration. Cell 125, 801-814 (2006).
21. Lein, E. S. et al. Genome-wide atlas of gene expression in the adult mouse brain. Nature 445, 168-176 (2007).
22. Burright, E. N. et al. SCA1 transgenic mice: a model for neurodegeneration caused by an expanded CAG trinucleotide repeat. Cell 82, 937-948 (1995).
23. Lam, Y. C. et al. ATAXIN-1 interacts with the repressor Capicua in its native complex to cause SCA1 neuropathology. Cell 127, 1335-1347 (2006).
24. Watase, K. et al. A long CAG repeat in the mouse Sca1 locus replicates SCA1 features and reveals the impact of protein solubility on selective neurodegeneration. Neuron 34, 905-919 (2002).
25. Bowman, A. B. et al. Duplication of Atxn1l suppresses SCA1 neuropathology by decreasing incorporation of polyglutamine-expanded ataxin-1 into native complexes. Nature Genet. 39, 373-379 (2007).
26. Serra, H. G. et al. RORα-mediated Purkinje cell development determines disease severity in adult SCA1 mice. Cell 127, 697-708 (2006).
27. Sampath, J. et al. Human SPF45, a splicing factor, has limited expression in normal tissues, is overexpressed in many tumors, and can confer a multidrug-resistant phenotype to cells. Am. J. Pathol. 163, 1781-1790 (2003).
28. Chaouki, A. S. & Salz, H. K. Drosophila SPF45: A bifunctional protein with roles in both splicing and DNA repair. PLoS Genet 2, e178 (2006).
29. Lallena, M. J., Chalmers, K. J., Llamazares, S., Lamond, A. I. & Valcarcel, J. Splicing regulation at the second catalytic step by Sex-lethal involves 3′ splice site recognition by SPF45. Cell 109, 285-296 (2002).
30. Yue, S., Serra, H. G., Zoghbi, H. Y. & Orr, H. T. The spinocerebellar ataxia type 1 protein, ataxin-1, has RNA-binding activity that is inversely affected by the length of its polyglutamine tract. Hum. Mol. Genet. 10, 25-30 (2001).
31. Zuccato, C. et al. Widespread disruption of repressor element-1 silencing transcription factor/neuron-restrictive silencer factor occupancy at its target genes in Huntington's disease. J. Neurosci. 27, 6972-6983 (2007).
32. Auerbach, W. et al. The HD mutation causes progressive lethal neurological disease in mice expressing reduced levels of huntingtin. Hum. Mol. Genet. 10, 2515-2523 (2001).
33. Van Raamsdonk, J. M. et al. Loss of wild-type huntingtin influences motor dysfunction and survival in the YAC128 mouse model of Huntington disease. Hum. Mol. Genet. 14, 1379-1392 (2005).
34. Leavitt, B. R. et al. Wild-type huntingtin reduces the cellular toxicity of mutant huntingtin in vivo. Am. J. Hum. Genet. 68, 313-324 (2001).
35. Cattaneo, E., Zuccato, C. & Tartari, M. Normal huntingtin function: an alternative approach to Huntington's disease. Nature Rev. Neurosci. 6, 919-930 (2005).
36. Thomas, P. S. Jr et al. Loss of endogenous androgen receptor protein accelerates motor neuron degeneration and accentuates androgen insensitivity in a mouse model of X-linked spinal and bulbar muscular atrophy. Hum. Mol. Genet. 15, 2225-2238 (2006).
37. Zuccato, C. et al. Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nature Genet. 35, 76-83 (2003).
38. Friedman, M. J. et al. Polyglutamine domain modulates the TBP-TFIIB interaction: implications for its normal function and neurodegeneration. Nature Neurosci. 10, 1519-1528 (2007).
39. Li, A., Piccardo, P., Barmada, S. J., Ghetti, B. & Harris, D. A. Prion protein with an octapeptide insertion has impaired neuroprotective activity in transgenic mice. EMBO J. 26, 2777-2785 (2007).
40. Harris, D. A. & True, H. L. New insights into prion structure and toxicity. Neuron 50, 353-357 (2006).
41. Shen, J. & Kelleher, R. J. III. The presenilin hypothesis of Alzheimer's disease: evidence for a loss-of-function pathogenic mechanism. Proc. Natl Acad. Sci. USA 104, 403-409 (2007).
42. Van Broeck, B., Van Broeckhoven, C. & Kumar-Singh, S. Current insights into molecular mechanisms of Alzheimer disease and their implications for therapeutic approaches. Neurodegener. Dis. 4, 349-365 (2007).
43. Rual, J. F. et al. Towards a proteome-scale map of the human protein-protein interaction network. Nature 437, 1173-1178 (2005).